ROMEO ISIDRO: Open Payments
NPI 1558393660 · NORTHRIDGE, CA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$142,657 in 279 payments from 17 companies in 2025. Trend: 2023 $162,446 · 2024 $151,837 · 2025 $142,657
Speaker / faculty: $117,211Consulting: $9,823Travel & lodging: $9,288Food & beverage: $6,329Education: $7
| Company | Payments | Amount |
|---|---|---|
| Neurocrine BioSciences, Inc. | 92 | $72,811 |
| Teva Pharmaceuticals USA, Inc. | 68 | $47,044 |
| ACADIA Pharmaceuticals Inc | 19 | $13,499 |
| ABBVIE INC. | 29 | $7,697 |
| E.R. Squibb & Sons, L.L.C. | 15 | $398 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 12 | $259 |
| Bausch Health US, LLC | 11 | $217 |
| Otsuka America Pharmaceutical, Inc. | 8 | $177 |
| Vanda Pharmaceuticals Inc. | 4 | $137 |
| Alpha Cognition USA, Inc. | 6 | $99 |
Products named: INGREZZA, AUSTEDO XR, NUPLAZID, VRAYLAR, COBENFY, CAPLYTA, REXULTI, APLENZIN.
Industry payments across CA — which companies pay providers there.
